Currently the arrangement of systemic adjuvant therapy for breast cancer is based on clinical and pathological prognostic and/or predictive factors such as estrogen receptor (ER), progesterone receptor (PgR) and human epidermal growth factor receptor type II (HER2) status [4]. This evidence concerns the gene ESR1 and breast carcinoma.